معرفی
Dr. Phillip Kantharidis is a Senior Research Fellow at Monash University, affiliated with the Department of Diabetes within the School of Clinical Sciences. He leads an active research group focused on diabetic complications, particularly nephropathy and atherosclerosis, and is accepting PhD students for projects on pro-resolution therapies and lipoxin A4.
- PhD in Molecular Biology, University of Melbourne (1993)
- BSc (Hons) in Virology, University of Melbourne (1983)
His research centers on the interplay between genetic, fibrotic, and inflammatory factors in diabetes. Key interests include cytokines, growth factors, microRNAs, and endogenous molecules like resolvins and lipoxin A4, which modulate pathological signaling. His lab uses RNA-seq to identify predictive biomarkers in biological fluids. These efforts aim to develop novel treatments targeting multiple diabetic complications.
The 15 most recent publications highlight a strong focus on diabetic kidney disease and cardiovascular dysfunction, with emerging themes in inflammation resolution, microRNA regulation, and therapeutic analogues. Articles are published in high-impact journals such as Kidney International, Cardiovascular Diabetology, and International Journal of Molecular Sciences, demonstrating translational and mechanistic depth.
Dr. Kantharidis has contributed to significant research outputs, including articles, reviews, and commentaries, with recent work gaining attention in news outlets and social media. While no specific awards are listed, his work is recognized through citations and collaborative projects.
He serves as a Chief Investigator on research grants, including a completed project on a novel endogenous inhibitor for diabetic nephropathy. He mentors PhD students and collaborates extensively with researchers such as Professor Merlin Cooper. His laboratory, the Kantharidis Group, is a key contributor to diabetes research at Monash, with a focus on molecular mechanisms and therapeutic innovation.
His research contributes to the UN Sustainable Development Goals, particularly in advancing health and well-being through biomedical innovation.
